Gilead Sciences, Inc. (GILD) operating KPIs
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)
Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%
Gilead Sciences equity method & fair value option biotech investments carrying value ($M) ($M)
Form 10-Q / 10-K Note 3 Fair Value & Note 4 Equity Securities
Latest, FY2025
393
Period ended Dec 31, 2025
Change on a year earlier
+1.8%
386 in FY2024
History
4 years
Since FY2022
Sources
4
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Equity method & fair value option biotech investments carrying value ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 393 | +1.8% | Form 10-Q (filed 2026-08-06) ↗ |
| FY2024 | Dec 31, 2024 | 386 | +13.5% | Form 10-K (filed 2026-02-24) ↗ |
| FY2023 | Dec 31, 2023 | 340 | -19.6% | Form 10-K (filed 2025-02-28) ↗ |
| FY2022 | Dec 31, 2022 | 423 | – | Form 10-K (filed 2024-02-23) ↗ |
Breakdown
What makes up equity method & fair value option biotech investments carrying value ($m)
- Equity method investment in Arcus Biosciences, Inc. — Fair value carrying amount ($M)749 · FY2025
- Equity method investment in Galapagos NV / Lakefront Biotherapeutics NV — Fair value carrying amount ($M)551 · FY2025
- Other equity method investments (incl. Assembly Biosciences) — Fair value carrying amount ($M)183 · FY2025
Cite this data
StockData. (2026). Gilead Sciences Equity method & fair value option biotech investments carrying value ($M) ($M), annual FY2022–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/eq_method_carrying
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.